he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源住址
上一页:哪些抗菌药物可诱发帕金森氏症?
下一页:中国生酮饮食疗法专家协商指南解读
- 2022-05-05早期病症的症状 早期病症症有哪些症状
- 2022-04-262013年该协会抗癫痫联合会抗癫痫药使用指南
- 2022-03-15LEEP手术知道多少?
- 2022-03-14白癜风症状 身体出现白斑时要小心
- 2022-01-31小儿癫痫病症状乏善可陈
- 2022-01-17成年人为什么会患癫痫病 癫痫病症状
- 抗癫痫药物预防新发癫痫:任重而道远
- 贝安健康:常见的妇科炎症有哪些类型?
- 疾病新知:毛囊性白癜风
- 癫痫猝死:凶手是谁?
- Cell重磅:解决了近百年的问题!研究发现了闪过记忆的潜在机制
- 原发性小肠淋巴管扩张症一例
- 自闭症儿童应考虑胃肠道症状
- FDA批准Aptiom用于治疗患者癫痫发作
- 警惕:利培酮维持治疗中锥体外部症状
- 比较好治疗增生性疣状白斑
- 75%存活出院!郑大一附院ECMO暴发性心肌炎治疗经验
- 癫痫患者手术评估新型工具
- NICE推荐将Elmiron(戊糖多钠)治疗膀胱疼痛综合征
- 严禁挤占!长期在职不在职,清退!
- Eur Respir J:评估慢性支气管炎和危险因素
- 断奶并不可怕,更不用说紧张了,应该这样做
- 羊角病能生孩子吗?
- 拔罐疗法 中医拔罐的治疗机制和方法
- 预测癫痫患者再入院风险
- 不注意这些问题,吃多少药都没用!
- 月经性癫痫患者妊娠期癫痫控制更好
- LEEP手术知道多少?
- 白癜风症状 身体出现白斑时要小心
- Diabetes Obes Metab:恩格列净对肝脂肪变性和纤维化标志物的影响及其与心肾结局的关系
- 癫痫治疗障碍仍难以克服
- Rheumatology:甘氨酸通过SAM介导的GPX4类风湿性关节炎启动子甲基化铁浓度变化研究
- 20120328健康来了:范志红讲芹菜叶的功效和作用
- 【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- 为什么女性癫痫病较难治愈
- 切除术学习:内镜下经三脑室入路治疗颅内脊索瘤
- 静注药物或阻碍癫痫持续患者预后
- 帕金森氏症的症状 睡觉中犯帕金森氏症会有哪些表现
- 治疗癫痫病处方要怎么治疗好啊
- 癫痫病必要怎样治疗 癫痫病治疗要多少钱
- 患癫痫病怎么治疗比较快
- 羊癫疯能治好吗 治疗不易需要多加注意防止猝死
- 青少年癫痫病怎么疗法最彻底
- 原发癫痫病能治疗者吗
- 使用嗪 3 天后,患者发生躁狂砸了监护仪?!这类抗生素脑病值得警惕!
- 青年人癫痫病因是什么呢